SCHEMBL7954092

SCHEMBL7954092

O=C(CCCC(=O)ON1C(=O)CCC1=O)OCCOC(=O)CCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.40
ALOX12 P18054 1/20 0.36
TDP1 Q9NUW8 1/20 0.34
PSMB8 P28062 2/20 0.33
BRD4 O60885 1/20 0.33
PSMB5 P28074 1/20 0.33
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 2/20 0.33
KMT2A Q03164 1/20 0.33
RECQL P46063 1/20 0.32
CASP6 P55212 1/20 0.32
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
GSTP1 P09211 1/20 0.31
DNM1 Q05193 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9972406 0.95 DGKA (0.37) DGKAALOX12TDP1PSMB8BRD4
SCHEMBL141048 0.93 ADRA2A (0.36) DGKAALOX12TDP1PSMB8PSMB5
SCHEMBL17563496 0.92 SMN1; SMN2 (0.41) DGKAALOX12PSMB8BRD4PSMB5
SCHEMBL310052 0.92 MGLL (0.37) DGKAALOX12PSMB8BRD4PSMB5
SCHEMBL9972409 0.92 DGKA (0.41) DGKAALOX12TDP1PSMB8BRD4
SCHEMBL34383 0.91 SMN1; SMN2 (0.36) ALOX12PSMB8PSMB5SMN1; SMN2KMT2A
SCHEMBL22777675 0.91 SMN1; SMN2 (0.36) ALOX12PSMB8PSMB5SMN1; SMN2KMT2A
SCHEMBL17637586 0.90 DGKA (0.43) DGKAALOX12TDP1PSMB8BRD4
SCHEMBL15760609 0.90 PRKCA (0.33) DGKAALOX12PSMB8BRD4PSMB5
SCHEMBL9978168 0.90 MAPK1 (0.44) DGKABRD4SMN1; SMN2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia SUNBIO INC. (KR) 2014-06-05 US disclosed
US-20130048077-A1 GEL ELECTROLYTE AND DYE-SENSITIZED SOLAR CELL USING THE SAME SAMSUNG SDI CO., LTD. (KR) 2013-02-28 US disclosed
US-20100051097-A1 GEL ELECTROLYTE AND DYE-SENSITIZED SOLAR CELL USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2010-03-04 US disclosed
US-6280474-B1 Devices for tissue repair and methods for preparation and use thereof NEUCOLL, INC. 2001-08-28 US disclosed
US-6083522-A TISSUE IMPLANTS WITH CHANNELS AND LOAD DISTRIBUTION DEVICE FOR HOLDING SUTUTES NEUCOLL, INC. (US) 2000-07-04 US disclosed
WO-1998030141-A2 DEVICES FOR TISSUE REPAIR AND METHODS FOR PREPARATION AND USE THEREOF COHESION TECHNOLOGIES, INC. (US) 1998-07-16 WO disclosed
WO-1998030252-A1 METHODS AND APPARATUSES FOR MAKING SWELLABLE UNIFORMLY SHAPED DEVICES FROM POLYMERIC MATERIALS COHESION TECHNOLOGIES, INC. (US) 1998-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia GLA, LPO, MUC1 DGKA 1282/4885ALOX12 150/4885TDP1 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.